Proteinase inhibitors reduce basement membrane degradation by human breast cancer cell lines

British Journal of Cancer

Volumn 75, Issue 7, 1997, Pages 951-959

  Stonelake, P S ^a,b   Jones, C E ^a   Neoptolemos, J P ^a   Baker, P R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

Basement membrane; Breast cancer; Invasion; Proteinase inhibitors; Proteinases

Indexed keywords

ALOXISTATIN; AMILORIDE; AMINOCAPROIC ACID; ANTIMETASTATIC AGENT; APROTININ; ASPARTIC PROTEINASE; B 894; CATHEPSIN B; CATHEPSIN D; CATHEPSIN L; CYSTEINE PROTEINASE; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPSTATIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BASEMENT MEMBRANE; BREAST CANCER; CANCER CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; ISOTOPE LABELING; METASTASIS INHIBITION; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

EID: 0030935738     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.166     Document Type: Article

References (51)

1. Alkjaersig N, Fletcher AP and Sol S (1959) ε-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem 234: 832-837
2. Azzam HS, Arand G, Lippman ME and Thompson EW (1993) Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst 85: 1758-1764
3. Barrett AJ (1477) Cathepsin D and other carboxyl proteinases. In Proteinases in Mammalian Cells and Tissues, Barrett AJ (ed.), pp. 209-248. Elsevier/North Holland Biomedical: Amsterdam
4. Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamai M and Hanada K (1982) L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B. H and L. Biochem J 201: 189-198
5. Boike G, Lah T, Sloane BF, Rozhin J, Honn K, Guirguis R, Strache ML, Liotta LA and Schiffmann E (1991) A possible role for cysteine proteinases and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res 1: 333-340
6. Briozzo P, Morrisset F, Capony F, Rougeol C and Rochefort H (1988) In vitro degradation of extracellular matrix with Mr52000 cathepsin D secreted by breast cancer cells. Cancer Res 48: 3688-3692
7. Brünner N, Boysen B, Romer J and Spang-Thomsen M (1993) The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Res Treat 24: 257-264
8. Buck MR, Karustis DG, Day NA, Honn KV and Sloane BF (1992) Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282: 273-278
9. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD and Balkwill FR (1993a) Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131
10. Davies B, Brown PD, East N, Crimmin MJ and Balkwill FR (1993b) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 53: 2087-2091
11. DeClerck YA and Imren S (1994) Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 30A: 2170-2180
12. Doherty AM, Sirear I, Kornberg BE, Quin J, Winters RT, Kaltenbronn JS, Taylor MD, Batley BL, Rapundalo SR, Ryan MJ and Painchaud CA (1992) Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors. J Med Chem 35: 2-14
13. Ellis V and Dano K (1992) The urokinase receptor and the regulation of cell surface plasminogen activation. Fibrinolysis 6: (suppl.4): 27-34
14. Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res 50: 6130-6138
15. Fritz H and Wunderer G (1983) Biochemistry and applications of aprotinin. the kallikrein inhibitor from bovine organs. Arzneim Forsch Drug Res 33: 479-494
16. Gabrijelcic D, Svetic B, Spaic D, Skrk J, Budihna M, Dolenc I, Popovic T, Cotic V and Turk V (1992) Cathepsins B, H and L in human breast cancer. Eur J Clin Chem Clin Biochem 30: 69-74
17. Garcia M, Derocq D, Pujol P and Rochefort H (1990) Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5: 1809-1814
18. Hayakawa T, Yamashita K, Ohuchi E and Shinagawa (1994) Cell growth-promoting activity of tissue of metalloproteinases-2 (TIMP-2). J Cell Sci 107: 2373-2379
19. Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V and Brünner N (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14: 297-307
20. Isgar B, Jones CE, Stonelake PS, Neoptolemos JP and Baker PR (1991) The effect of proteinase inhibitors on growth and cathepsin D levels of human breast cancer cells. Br J Cancer 63: (suppl. XIII): 21
21. Johnson MD, Jeffrey AT, Lippman ME and Dickson RB (1993) The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res 53: 873-877
22. Kellen JA, Mirakian A and Kolin A (1988) Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res 8: 1373-1376
23. Kikuchi Y, Kizawa I, Oomori K, Matsuda M and Kato K (1986) Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amount of ascites. Acta Obstet Gynecol Scand 65: 453-456
24. Kikuchi Y, Kizawa I, Oomori K, Miyauchi M, Kita T, Sugita M, Tenjin Y and Kato K (1987) Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res 47: 592-596
25. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T and Terao T (1992) Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52: 3610-3614
26. Lim Y-T, Sugiura Y, Laug WE, Sun B, Garcia A and DeClerk YA (1996) Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. J Cell Physiol 167: 333-340
27. Mangel WF, Toledo DL, Nardulli AM, Reiner GCA, Norman MJ and Katzenellenbogen BS (1988) Plasminogen activators in human breast cancer cell lines: hormonal regulation and properties. J Steroid Biochem 30: 79-88
28. Mignatti P, Robbins E and Rifkin DB (1986) Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487-498
29. Miles LA and Plow EF (1985) Binding and activation of plasminogen on the platelet surface. J Biol Chem 260: 4303-4311
30. Minafra S, Morello V, Glorioso F, La Fiura AM, Tomasino RM, Feo S, McIntosh D and Woolley DE (1989) A new cell line (8701-BC) from primary ductal infiltrating carcinoma of human breast. Br J Cancer 60: 185-192
31. Montcourrier P, Mangeat PH, Salazar G, Morisset, Sahuquet A and Rochefort H (1990) Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. Cancer Res 50: 6045-6054
32. Monteagudo C, Merino MJ, Josefina S-J, Liotta LA and Stetler-Stevenson WG (1990) Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 136: 585-592
33. Morris VL, Tuck AB, Wilson SM, Percy D and Chambers AF (1993) Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines. Clin Exp Metastasis 11: 103-112
34. Mosquera D, Jones CEB and Goldman MD (1991) The effect in-vitro of harvesting enzymes on endothelial cell adhesion to PTFE. Surg Res Comm 11: 193-199
35. Nemeth JA, Rafe A, Steiner M and Goolsby CL (1996) TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res 224: 110-115
36. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC and Miskin R (1988) Effects of inhibitors of plasminogen activator, serine proteinases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48: 3307-3312
37. Reiter LS, Kruithof EKO, Cajot J-F and Sordat B (1993) The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon cells. Int J Cancer 53: 444-450
38. Rozhin J, Gomez AP, Ziegler GH, Nelson KK, Chang YS, Fong D, Onoda JM, Honn KV and Sloane BF (1990) Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors. Cancer Res 50: 6278-6284
39. Rozhin J, Sameni M, Ziegler G and Sloane BF (1994) Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54: 6517-6525
40. Schmitt M, Janicke F and Graeff H (1992) Tumor-associated proteases. Fibrinolysis 6: (suppl.4): 3-26
41. Scragg MA and Ferreira LR (1991) Evaluation of different staining procedures for the quantification of fibroblasts cultured in 96-well plates. Anal Biochem 198: 80-85
42. Shoji-Kasai Y, Sensho M, Iwashita S and Imahori K (1988) Thiol protease-specific inhibitor E-64 arrests human epidermoid carcinoma A431 cells at mitotic metaphase. Proc Natl Acad Sci 85: 146-150
43. Sledge GW, Qulali M, Goulet R, Bone EA and Fife R (1995) Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 87: 1546-1550
44. Stephens RW, Pollanen J, Tapiovara H, Leung K-C, Sim P-S, Salonen E-M, Ronne E, Behrendt N, Dano K and Vaheri A (1989) Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 108: 1987-1995
45. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR and Dickson RB (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544
46. Towle MJ, Lee A, Maduakor C, Schwartz CE, Bridges AJ and Littlefield BA (1993) Inhibition of urokinase by 4-substituted Benzo[b]thiophene-2-carboxamidines: an important new class of selective urokinase inhibitor. Cancer Res 53: 2553-2559
47. Uetsuji S, Yamamura M, Takai S, Hioki K and Yamamoto M (1992) Effect of aprotinin on metastasis of Lewis lung tumor in mice. Jpn J Surg 22: 439-442
48. Vasishta A, Baker PR, Preece PE, Wood RAB and Cushieri A (1988) Inhibition of proteinase-like peptidase activities in serum and tissue from breast cancer patients. Anticancer Res 8: 785-790
49. Vassalli J-D and Belin D (1987) Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214: 187-191
50. Yagel S, Warner AH, Nellans HN, Lala PK, Waghorne C and Denhardt DT (1989) Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells. Cancer Res 49: 3553-3557
51. Yee C and Shui RPC (1986) Degradation of endothelial basement membrane by human breast cancer cell lines. Cancer Res 46: 1835-1839